Thesis
Profitable med-device franchisor with $537M cash trades through a contested go-private bid while revenue stabilizes — governance chaos and margin compression are the deciding factors
InMode sells energy-based aesthetic devices and generates recurring consumables revenue, but full-year 2025 revenue fell 6% and operating margins compressed sharply as the North America sales structure was rebuilt. A $16.20/share go-private proposal from the CEO group and a competing Steel Partners bid have triggered litigation over director independence, making corporate resolution the near-term binary. If no adequate transaction clears, InMode must demonstrate organic margin recovery with a reconstituted leadership team facing a patent challenge on its Morpheus8 line.
Focus
Competing acquisition proposals under legal challenge with court hearing on July 19, 2026
Q3 2026
Bull
If the Haifa District Court lifts the injunction after the July 19 hearing and the special committee proceeds with a full auction, competitive tension between the CEO group and Steel Partners could push the final acquisition price above $16.20/share, unlocking value well above the cash-rich balance sheet (~$555M) at a sub-1x revenue multiple. A clean go-private transaction would also remove ongoing concerns about declining operating margins and a challenged North America sales restructuring.
Bear
If the court determines that special committee directors lack sufficient independence, it could invalidate the review process or force reconstitution of the committee, substantially delaying any deal and allowing the current operational headwinds — margin compression, CFO departure, 2025 revenue decline — to reassert themselves as the primary narrative. Steel Partners previously submitted a proposal that was rejected in February 2026, raising the possibility that neither bid ultimately reaches an adequate threshold, as the prior transaction review concluded.
Unlock the full thesis for INMD.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialGenerated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.